Roe Catherine M, Odell Kevin W, Henderson Rochelle R
Division of Biostatistics and Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
J Clin Psychopharmacol. 2003 Apr;23(2):197-200. doi: 10.1097/00004714-200304000-00013.
Concomitant use of drugs that prolong the QT interval is a risk factor for torsades de pointes, a ventricular arrhythmia associated with sudden death. This study compared the concomitant use of drugs that may prolong the QT interval ("other QT drugs") among two groups of patients: one that took antipsychotics that may prolong the QT interval (the QT antipsychotic group, n = 1,750) and one that used antipsychotics that do not result in QT prolongation (the non-QT antipsychotic group, n = 1,139). Data were pharmacy claim and eligibility information from January 1, 2000, through December 31, 2000, from a research database of a large pharmacy benefit manager. Concomitant use of antipsychotics and other QT drugs was examined for each participant over a 3- to 12-month follow-up period. Results showed that 51% of QT antipsychotic group members used other QT drugs concomitantly for at least 1 day in the follow-up period. Logistic regression indicated that there was no significant difference between the QT antipsychotic and non-QT antipsychotic groups with concomitant use of other QT drugs when potential confounders were controlled ( p = 0.6013). Although female sex is a risk factor for drug-induced torsades de pointes, women were more likely to concomitantly use other QT drugs than men in both the QT (56.2% vs. 43.2%; p < 0.001) and non-QT (53.1% vs. 43.0%;p < 0.001) antipsychotic groups. Findings suggest that the use of other QT drugs is not being minimized among patients taking QT antipsychotics.
联用可延长QT间期的药物是尖端扭转型室速的一个风险因素,尖端扭转型室速是一种与猝死相关的室性心律失常。本研究比较了两组患者联用可能延长QT间期的药物(“其他QT药物”)的情况:一组服用可能延长QT间期的抗精神病药物(QT抗精神病药物组,n = 1750),另一组使用不会导致QT间期延长的抗精神病药物(非QT抗精神病药物组,n = 1139)。数据来自一家大型药房福利管理机构的研究数据库,涵盖2000年1月1日至2000年12月31日的药房报销申请和资格信息。在3至12个月的随访期内,对每位参与者联用抗精神病药物和其他QT药物的情况进行了检查。结果显示,QT抗精神病药物组中有51%的成员在随访期内至少有1天联用了其他QT药物。逻辑回归分析表明,在控制潜在混杂因素后,QT抗精神病药物组和非QT抗精神病药物组联用其他QT药物的情况无显著差异(p = 0.6013)。虽然女性是药物诱导的尖端扭转型室速的一个风险因素,但在QT抗精神病药物组(56.2%对43.2%;p < 0.001)和非QT抗精神病药物组(53.1%对43.0%;p < 0.001)中,女性比男性更有可能联用其他QT药物。研究结果表明,在服用QT抗精神病药物的患者中,其他QT药物的使用并未降至最低限度。